SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In the present study, we investigated the protective effect of the SGLT2 inhibitor dapagliflozin in alleviating NAFLD both in vivo and in vitro, and further clarified the role of AMPK activation in ameliorating hepatic lipid accumulation and the involvement of the AMPK-mTOR signaling pathway in autophagy induction.